NCT07860047Not yet recruitingPhase 2
Randomized Phase II study of multi-peptide vaccination and bispecific PSMAxCD3 antibody treatment in patients with biochemical relapse of prostate cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Oct 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- First submitted
- 23 Apr 2026
- Start date
- 30 Jun 2026
- Lead sponsor
- Universitaetsklinikum Tuebingen AöR
- Diseases
- Prostate cancer
- EU CT number
- 2025-522144-41-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 84
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Universitaetsmedizin Berlin KöR Coordinator of this site? Confirm its status | Berlin | Germany | Not yet recruiting |
| Universitaetsklinikum Essen (AoR) Coordinator of this site? Confirm its status | Essen | Germany | Not yet recruiting |
| National Center for Tumor Diseases (NCT) Heidelberg Coordinator of this site? Confirm its status | Heidelberg | Germany | Not yet recruiting |
| Universitaetsklinikum Tuebingen AöR Coordinator of this site? Confirm its status | Tuebingen | Germany | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.